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Summary Adhesion of cancer cells to vascular endothelium is an important step in haematogenous metastasis of cancer. A human
hepatocellular carcinoma cell line, HepG2, strongly adheres to human umbilical vein endothelial cells (HUVECs) through the interaction of E-
selectin and its carbohydrate ligand sialyl Lewis X. In this study, we investigated alteration in integrin expression on HepG2 cells, which
follows the selectin-mediated initial adhesion of HepG2 cells to HUVECs. Expression of afil integrin was markedly increased when the
HepG2 cells adhered to HUVECs. Among the tested cytokines that are known to be produced by endothelial cells, recombinant hepatocyte
growth factor (rHGF) could replace the effect of HUVECs, and a similar increase in integrin expression was observed by the addition of 20 ng
ml-' rHGF to HepG2. The increment of a2fil integrin expression was significantly inhibited by anti-HGF neutralizing antibody treatment.
HepG2 cells expressed a2, a6, f, and 4 integrin subunits, but expression of integrins other thana2fi was not affected by the rHGF treatment.
The rHGF treatment of HepG2 cells resulted in augmented adhesion to immobilized collagen. This augmentation in adhesion to collagen was
completely blocked by the addition of anti-a2- or anti-,B-integrin antibody. In double-chamber chemoinvasion experiments, transmigration of
the HepG2 cells through extracellular matrix (ECM) gel was significantly accelerated by co-cultivation with HUVECs. A similar level of
enhancement in transmigration activity of the cancer cells was observed by the addition of rHGF. Our interpretation of the results described
above is that the cancer cells received stimulation from cytokines, such as HGF, presented by vascular endothelial cells, following the initial
adhesion of cancer cells via selectins. This resulted in the secondary increment in the expression of cell adhesion molecules, such as the a2f,
integrin, and led to the augmented adhesive activities of cancer cells towards extracellular matrices at vascular walls. We suggest that this
sequence of events is involved in the facilitated migration of some cancer cells to extravascular tissues.
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Haematogenous metastasis of cancer is a complicated process
consisting of multiple steps. The attachment of cancer cells to
vascular endothelium is possibly initiated by the cell adhesion
mediated by E-selectin on endothelial cells and carbohydrate
ligands on cancer cells (Hakomori, 1992; Majuri et al, 1992;
Dejana et al, 1992; Takada et al, 1991, 1993). The only exceptions
known are non-epithelial malignant cells, such as melanoma or
neuroblastoma and fibrosarcoma, which bind to endothelial cells
mainly through VCAM-1. The carbohydrate determinants, sialyl
Lewis A and sialyl Lewis X, expressed on cancer cells serve as
ligands for E-selectin (Lowe et al, 1990; Phillips et al, 1990;
Takada et al, 1991, 1993). Sialyl Lewis A is primarily involved in
the adhesion ofcancers ofdigestive organs, while sialyl Lewis X is
mainly involved in the adhesion of liver, breast, lung and ovary
cancer cells to endothelial cells (Majuri et al, 1992; Dejana et al,
1992; Takada et al, 1991, 1993).
The selectin-carbohydrate interaction can be regarded as an
important factor that facilitates adhesion of cancer cells to
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endothelial cells during the course of haematogenous metastasis
(Merwin et al, 1992; Giavazzi et al, 1993). In vitro experiments
indicated that E-selectin expression on endothelial cells is induced
by cytokines, such as interleukin 1 (IL-1) and/or tumour necrosis
factor alpha (TNFax) (Bevilacqua et al, 1987), suggesting that this
cell adhesion system is heavily involved, especially in cancer
metastasis into damaged and/or inflamed tissues. Some cancer
cells are known to express IL-1 and other cytokines that activate
endothelial cells (Li et al, 1992; Alexandroffet al, 1994; Hayashi et
al, 1994), and these cytokines, through the induction ofcell surface
E-selectin, would also facilitate the adhesion of cancer cells to
endothelial cells. Serum E-selectin levels are known to be elevated
in patients with cancers, reflecting the enhanced expression of E-
selectin in the vessel walls ofthese patients (Banks et al, 1993; Ye
et al, 1995). Recent immunohistochemical studies also indicate
that small vessels adjacent to cancer nests express E-selectin
strongly (Ye et al, 1995). All these findings suggest the importance
ofE-selectin-mediated cell adhesion in cancer metastasis.
However, the sequence ofevents following the initial step ofcell
adhesion and leading to the extravasation of cancer cells remains
largely unknown. Here, we have studied the expression of inte-
grins on cancer cells after the cells underwent the selectin-medi-
ated initial adhesion process to endothelial cells. We also tried to
identify the molecular species of affected integrins and cytokines
involved in the regulation oftheir expression.
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MATERIALS AND METHODS
Cell culture, chemical reagents and antibodies
The human hepatocellular cancer cell line, HepG2 (ATCC,
Rockville, MD, USA), was maintained in Dulbecco's modified
Eagle medium (DMEM, GIBCO/BRL, Grand Island, NY, USA),
supplemented with 10% fetal calf serum (FCS). Human umbilical
vein endothelial cells (HUVECs, Seikagaku Kogyo, Tokyo, Japan)
were maintained in Daigo's T medium (Nissui Seiyaku, Tokyo)
supplemented with 10% FCS and 2 ng ml-' recombinant bFGF
(kindly provided by Takeda Pharmaceutical Osaka, Japan). Purity
of HUVECs was ascertained by flow cytometric analysis using
anti-factor VIII antibody and was more than 99% throughout the
experiments described in this study.
Recombinant human IL-i1 was kindly provided by Otsuka
Pharmaceutical (Tokushima, Japan). Human MIP- P, recombinant
human IL-8 and human keratinocyte growth factor (KGF) were
obtained from Pepro Tech (Rocky Hill, NJ, USA). Recombinant
human hepatocyte growth factor (rHGF) was purified from culture
medium of CHO cells transfected with plasmid containing the
human HGF cDNA (Nakamura et al, 1989). Recombinant human
heparin-binding epidermal growth factor (rHB-EGF) was kindly
provided by Dr S Higashiyama, Osaka University.
Antibodies directed to CDl la (a,-subunit, MHM24) and CD18
(p2-subunit, MHM23) integrins were purchased from Dako
(Glostrup, Denmark); those directed to CDl lb (am-subunit, D12),
CD1lc (ax-subunit, S-HCL-3), P3 (7F12) and 04 (AA3) subunits
were from Becton Dickinson (Mountain View, CA, USA); anti-
CD29 (0,-subunit, 4B4) was from Coulter Immunology (Hialeah,
FL, USA); anti-CD49a antibody (a,-subunit, TS2/7) was from T
Cell Diagnostics (Cambridge, MA, USA); anti-CD49e antibody
(a5-subunit, KH33) was from Seikagaku Kogyo (Tokyo, Japan);
and antibodies to CD49b (a2subunit, Gi9), CD49c (a3-subunit, M-
KID2), CD49d (a4-subunit, HP2/1) and CD49f (a6subunit,
GoH3) were obtained from Immunotech (Marseille, France).
Monolayer cell adhesion assay using HUVECs
HUVECs were stimulated with 2 ng ml-' recombinant IL-iI for
4 h in 24-well plates. HepG2 cells (5 x 105 cells per well) were
added and the plate was incubated with rotation at 90 r.p.m. for
20 min at room temperature (Takada et al, 1991, 1993). After non-
adherent cells were washed out three times with phosphate-
buffered saline (PBS), the number of attached cells was counted
directly under a microscope. Monoclonal anti-E-selectin, anti-
ICAM-1 and anti-VCAM-l antibodies (BBA2, BBA4 and BBA6,
all murine IgG,) were obtained from British Biotechnology,
Abingdon, Oxon, UK. These antibodies were preincubated with
HUVECs at 50 jg ml-' for 30 min at 37°C before the adhesion
experiments with HepG2 cells for inhibition. Monoclonal anti-
bodies SNH-3 (specific to sialyl Lewis X, kindly supplied by Dr
Sen-Itiroh Hakomori, Biomembrane Institute, Seattle, WA, USA)
and 2D3 (specific to sialyl Lewis A, established in our laboratory)
were preincubated with HepG2 cells at 25 jig ml-' for 30 min at
room temperature before application to the monolayer of
HUVECs (Takada et al, 1991, 1993).
Flow cytometric analysis for cell surface integrin
expression
To study the change in integrin expression induced by selectin-
mediated cell adhesion, HepG2 cells were adhered to the
monolayerofHUVECs and co-cultured for 24 h at 37°C. To assess
the effect of cytokines on integrin expression, HepG2 cells were
cultured with 20 ng ml-' rHGF or other cytokines for 24 h at
37°C. Flow cytometric analysis of HepG2 cells was performed
using FACScan (Becton Dickinson Immuno-cytometry System,
Mountain View, CA, USA) as described previously (Ohmori et al,
1993). The indirect immunofluorescence method was applied for
staining ofHepG2 cell integrins, using an anti-integrin antibody as
the first antibody and a fluorescein isothiocyanate (FITC)-labelled
mouse anti-Ig as the second antibody (Cappel, Malvern, PA, USA).
Experiments for the inhibition of integrin expression were
performed using rabbit antisera raised against human rHGF
(Montesano et al, 1991). Rabbit anti-IL-IJ (kindly supplied by
Otsuka Pharmaceutical, Tokushima, Japan) and anti-bFGF anti-
bodies (kindly provided by Takeda Pharmaceutical, Osaka, Japan)
served as control antibodies in these experiments. These antibodies
were added at 1/50 - 1/250 dilution to the mixed culture ofHepG2
and HUVECs for 24 h at 37°C before flow cytometric analysis.
Cellular enzyme-linked immunosorbent assay (CELISA)
for cell surface integrins
Quantitative CELISA for total integrin expression was performed
on the monolayer of HepG2 cells that were grown in 96-well
plates. After incubation with culture medium containing 20 ng
ml-' rHGF for 24 h unless otherwise indicated, the plate was
washed twice with PBS and fixed by adding 0.1% glutaraldehyde
for I h at room temperature. The plate was washed three times
with PBS and unbound surfaces were blocked with 5% bovine
serum albumin (BSA) in PBS overnight at 4°C. After washing
twice with PBS, 50 gl ofthe primary antibodies was added to the
wells and incubated for 1 h at room temperature. After washing
three times with PBS, a 1:100 dilution of peroxidase-conjugated
goat anti-mouse IgG (Zymed Laboratories, San Francisco, CA,
USA) was added as the secondary antibody and incubated for 1 h
at room temperature. The excess enzyme conjugates were then
removed by washing three times with PBS, and 50 gl of the
substrate, O-phenylenediamine in citrate buffer, containing
0.015% hydrogen peroxide, was added to each well for 10-15 min
at room temperature. The colour reaction was stopped with 2M
sulphuric acid (50 gl per well), and absorbance was measured
using a microplate reader (Tosoh, Tokyo) at 492 nm.
Cell attachment assay to ECM molecules
The 24-well plates were coated with 5 gg ml collagen I
(Seikagaku Kogo, Tokyo) or 20 ,ug ml' laminin (Takara Shuzo,
Otsu, Japan) at 4'C overnight (Staatz et al, 1989; Carter et al,
1990), and the wells were washed three times with PBS. Unbound
surfaces were blocked with 0.5% BSA in PBS for I h, and again
the wells were washed three times with PBS. HepG2 cells (5 x
105), after the preincubation with 20 ng ml-' rHGF for 24 h, were
added in a volume of500gl per well to each substrate-coated well
and then incubated for 30 min at 37°C. The wells were then
washed three times with PBS to remove unattached cells. The
number ofattached cells was counted directly under a microscope.
Chemoinvasion assay
Invasion chambers with 6-mm-diameter filters (8-jim pore size)
were coated with 50 jig ml-' Matrigel (Collaborative Biomedical
Products, Bedford, MA, USA). The coated chambers were placed
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Figure 2 Flow cytometric analysis of augmentation of a21,1 integrin
expression on HepG2 cells by the co-cultivation with HUVECs (A) or by the
addition of rHGF (B). In A, HepG2 cells were co-cultured with (-) or without
(-) HUVECs for 24 h. In B, HepG2 cells were cultured in DMEM in the
presence (-) or absence (-) of 20 ng ml-' rHGF for 24 h. Stained using
anti-CD49b antibody
Figure 1 Contribution of known adhesion molecules and their ligands to the
adhesion of HepG2 cells to rIL-1 5-activated HUVECs. (A) Results of
pretreatment of HUVECs with anti-E-selectin, anti-ICAM-1 or anti-VCAM-1
antibody. HUVECs were treated with the respective antibody (50 9g ml-') for
30 min before the adhesion experiment. (B) Results of pretreatment of
HepG2 cells with anti-sialyl Lewis A (2D3), anti-sialyl Lewis X (SNH-3) or a
mixture of both antibodies. HepG2 cells were treated with antibodies (25 9g
ml-') for 30 min before the adhesion experiment.
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Figure 3 Effects of various cytokines on a2p,B integrin expression on HepG2
cells. HepG2 cells were cultured in DMEM containing rHGF (20 ng ml-'), KGF
(100 ng ml-'), IL-153 (2 ng ml-'), bFGF (2 ng ml-'), HB-EGF (10 ng ml-'), TGF-
(5 ng ml-'), IL-8 (10 ng ml-') or MIP-1 (100 ng ml-') for 24 h, and
expression of the oap, integrin was assessed by CELISA using anti-CD49b
antibody. The results are expressed as percentage absorbance of non-
treated HepG2 cells. Bars show s.d.
in 24-well plates. To examine the effect of adhesion to HUVECs
on the transmigration activity, HUVEC monolayers were formed
in the chambers, and HepG2 cells (7 x 104) suspended in DMEM
were added to the chambers. For examination ofthe effect ofHGF,
HepG2 cells were added to the upper chambers with 20 ng ml'
rHGF. The medium containing 20 gg ml- collagen I or medium
alone was added to each lower well ofthe 24-well plate. Cells were
cultured at 37°C for 72 h. At the end ofthe culture, the cells on the
upper surfaces ofthe filters were removed by wiping with a cotton
swab. The filters were fixed in ethanol and were stained with
Giemsa. The number of cells exuding to the lower surface was
counted in five independent visual fields under a microscope at x
200 (Albini et al, 1987).
RESULTS
Initial adhesion step of HepG2 cells to endothelial cells
HepG2 cells strongly adhered to rIL-l-activated HUVECs (Figure
1). The contribution ofcell adhesion molecules to the adhesion of
HepG2 cells was evaluated using specific monoclonal antibodies.
When the rIL-In-activated HUVECs were pretreated with anti-
bodies directed to E-selectin, ICAM- 1 or VCAM-1, adhesion was
significantly inhibited only by the treatment with anti-E-selectin
antibody (Figure IA). The effect ofanti-ICAM-l and anti-VCAM-
I antibodies was negligible. When HepG2 cells were treated with
anti-carbohydrate antibodies before adhesion to HUVECs, adhe-
sion of the cells was completely abrogated by pretreating the cells
with anti-sialyl Lewis X (Figure IB). These results indicate that
the sialyl Lewis X/E-selectin cell adhesion system plays a primary
role in the initial adhesion step ofHepG2 cells to HUVECs.
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Figure 4 Effect of concentration (A) and incubation time (B) on the
enhancement of integrin expression on HepG2 cells induced by the rHGF
treatment. (A) Dose dependency of a2 (0) and f, (0) integrin subunit
expression detected by CELISA using anti-CD49b and anti-CD29 antibodies.
HepG2 cells were cultured in DMEM containing varying concentrations of
rHGF for 24 h. (B) Time course of a2 (0) and P, (0) integrin subunit
expression. HepG2 cells were incubated in DMEM containing 20 ng ml-'
rHGF for 0, 10, 30 min or 1, 2, 4, 8 and 24 h. Each point represents the mean
absorbance above background of triplicate assays
Increased expression of integrins by prolonged culture
of HepG2 cells and effect of cytokines
To investigate any possible change in the integrin expression
following the first step ofadhesion, HepG2 cells were co-cultured
with HUVECs for 24 h and subjected to flow cytometric analysis.
The results demonstrated that the expression of a2[l integrin on
HepG2 cells was significantly increased by co-cultivation with
HUVECs (Figure 2A).
Next, HepG2 cells were treated with various cytokines that are
reported to be produced by endothelial cells, to determine which
cytokine produced by HUVECs was responsible for the observed
up-regulation of c2, integrin expression. The results of CELISA
are shown in Figure 3. Among the tested cytokines, rHGF had the
strongest up-regulating effect on the ac20[ integrin expression.
Some other cytokines, such as bFGF or IL-1i, enhanced the
expression, but only weakly. No significant change was noted by
the treatment with IL-8, MIP-1 [3 or KGF.
The enhancing effect of rHGF was confirmed by flow cyto-
metric analysis. After HepG2 cells were cultured in the presence
of 20 ng ml-1 rHGF for 24 h, the expression of cc,[, integrin on
HepG2 cells was up-regulated to the same level as that obtained by
the co-cultivation with HUVECs (Figure 2B).
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Figure 5 The expression of various integrins on HepG2 cells measured by
CELISA after 24 h incubation with (U) or without (O) 20 ng ml-' rHGF. Each
absorbance represents the mean value above background of duplicate
determinations
Characterization of HGF action on the integrin
expression of HepG2 cells
The dose-response ofaf21 integrin expression was determined by
CELISA after treatment of HepG2 cells with varying concentra-
tions ofrHGF for 24 h. Increase in the expression ofboth integrins
was correlated to the concentration ofrHGF, with maximal expres-
sions ofthe antigens being obtained by the treatment at 20 ng ml
(Figure 4A).
Figure 4B shows the time course of rHGF action on integrin
expression, indicating that an increase in integrin expression was
already detectable after 1 h, with an apparent maximum being
observed after 24 h.
HepG2 cells express the c2, 2a6, [3P and [4 integrin subunits, but
the al, (X3, cc4, 3 959 [2 and [3 integrin chains were not detected in
significant amounts. We investigated the expression of various
integrin subunits on HepG2 cells by CELISA. Increase of expres-
sion was most prominent for the [, integrin subunit (CD29),
followed by the cc2 subunit (CD49b) after treatment with 20 ng
ml-1 rHGF for 24 h. No significant change was observed in expres-
sion ofthe other integrins (Figure 5).
Table 1 Effect of anti-HGF neutralizing antibody on the enhancement of a2,J,
integrin expression induced by the addition of rHGF or by the co-cultivation
with HUVECs in HepG2 cells
Treatment of HepG2 cells Net increase in mean
fluorescence intensity (%)
Experiment 1
Addition of rHGF (20 ng ml-1) 100.0
Addition of rHGF (20 ng ml-') +anti-HGF 0.6
Experiment 2
Co-cultivation with HUVECs 100.0
Co-cultivation with HUVECs +anti-HGF 52.6
Co-cultivation with HUVECs +anti-bFGF 99.5
Co-cultivation with HUVECs +anti-IL-1 ,B 96.5
In experiment 1, the net increase in mean fluorescence intensity of a2-
integrin (CD49b) on HepG2 cells that had been treated with 20 ng ml-' (see
Figure 2B), compared with that of non-treated HepG2 cells, was taken as
100%. In experiment 2, the net increase in mean fluorescence intensity of a2-
integrin on HepG2 cells that had been co-cultured with HUVECs (see Figure
2A), was taken as 100%.
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Enhancement of adhesion to collagen and of
transmigratory activity
The attachment assay to collagen I and laminin of HepG2 cells
was carried out to investigate whether the increased expression of
aj, integrin really affects the adhesive behaviour of the HepG2
cells to the putative ECM ligands for the integrin. As shown in
Figure 6A, HepG2 cells cultured in the presence ofrHGF showed
an increased binding activity to collagen, the putative ligand for
the a2j, integrin. On the other hand, the attachment to laminin
showed no significant change. This result is in line with the finding
that the expression of the a6 integrin subunit on HepG2 cells
showed no change upon stimulation with rHGF, since laminin is
the putative ligand for thea6c61 integrin.
The adhesion of HGF-treated HepG2 cells to collagen was
nearly completely inhibited by the treatment with anti-a2 oranti-P1
antibodies, but not with anti-a6 antibody (Figure 6B). This result
indicates that the augmentation in the adhesion was caused by the
activation ofafi-integrin by rHGF.
We also performed chemoinvasion experiments to evaluate the
effect of the co-cultivation with HUVECs or of the addition of
rHGF on the transmigratory activity ofthe HepG2 cells (Figure 7).
In these experiments, the lower wells of the 24-well plates
contained collagen, and the cancer cells migrating through
Matrigel and appearing at the lower membrane surface were eval-
uated. HepG2 cells co-cultured with HUVECs had a higher
invading activity than non-treated HepG2 cells (Figure 7A). The
same level ofincrement in the transmigratory activity was attained
when HepG2 cells were stimulated with rHGF (Figure 7B).
Figure 6 Effects of rHGF on the attachment of the HepG2 cells to collagen
and laminin. In A, HepG2 cells were cultured in the presence (M) or absence
(O) of 20 ng ml-' rHGF for 24 h and allowed to attach for 30 min to wells
coated with collagen or laminin. Bars indicate s.d. Statistical significance
was tested by Student's t-test. In B, HepG2 cells, which had been cultured
with (-) or without (O) 20 ng ml-1 rHGF for 24 h, were allowed to attach for 30
min to the collagen-coated wells in the presence of blocking antibodies
directed to CD49b (a2-integrin), CD49f (a6-integrin) or CD29 (,B-integrin).
Bars indicate s.d.
Effect of anti-HGF antibody on integrin expression of
HepG2 cells
An inhibition experiment exploying neutralizing antisera against
rHGF was performed to determine whether the enhancement ofthe
integrin expression by HUVECs is mediated by HGF produced by
HUVECs. This rabbit antisera preparation completely inhibited
the up-regulation induced by rHGF. On the other hand, HUVEC-
induced enhancement ofthe a2o21 integrin expression was inhibited
by about 50%.
This result indicates that at least 50% ofthe enhancing effect on
the integrin expression, which was exerted by the co-cultivation
with HUVECs, is mediated by HGF produced by HUVECs. The
mechanisms involved in the other 50% remain unclear. One
possible explanation for the latter would be the additional action of
other cytokines that have a weak enhancing effect, such as bFGF
and/or IL-1,B. However, the addition of rabbit anti-IL-l or anti-
bFGF antibody did not abolish the enhancement of the integrin
expression (Table 1). Anotherpossibility would be that the neutral-
ization ofrHGF is difficult when the stimulative effect is conveyed
by direct physical contact between HUVECs and HepG2 cells.
DISCUSSION
Exudation of leucocytes to endothelial cells is known to be initi-
ated by the cell adhesion mediated by selectins and carbohydrate
ligands (Stoolman, 1989; Springer and Lasky, 1991). This is
followed by the second step of cell adhesion that is mediated by
integrins and corresponding molecules of the immunoglobulin
superfamily, such as ICAM-1 and VCAM-1, with this step
assumed to induce the exudation of leucocytes into extravascular
tissues (Stoolman, 1989; Springer and Lasky, 1991). LFA-1, the
ligand forICAM-1, and VLA-4, the ligand forVCAM-1, are abun-
dantly expressed on leucocytes. In contrast to this, expression of
LFA-1 or VLA-4 is relatively rare in epithelial cancer cells, while
a2, a3, a6, Bi and 4 integrin subunits are commonly expressed on
most cancer cells (Weinel et al, 1992; Albelda, 1993; Volpes et al,
1993; our unpublished results).
In this study, HepG2 cells did not express LFA-1 or VLA-4,
similar to many other epithelial cancer cells. The integrins
expressed significantly on HepG2 cells were a2, a6, and I4 inte-
grin chains. Following the first step of adhesion to endothelial
cells mediated by E-selectin and sialyl Lewis X, only the expres-
sion ofa2x20 integrin was enhanced on HepG2 cells by co-cultiva-
tion with HUVECs. This effect of HUVECs was mimicked by the
addition of rHGF to the culture medium. A significant portion of
the enhancing effect was identified to be owing to the action
of HGF produced by endothelial cells, by the experiments
using neutralizing antibody. MIP-lp and IL-8 are suggested to
be involved in the activation of leucocyte integrins in
leucocyte-endothelial adhesion (Kuijpers et al, 1992; Tanaka et al,
1993). In the case of HepG2 cells, MIP-1, and IL-8 were devoid
of any detectable effect on integrin expression. MIP-1j and IL-8
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Figure 7 Effect of rHGF or HUVECs on the transmigratory activity of HepG2
cells. The experimental procedures are shown in the insets of the figure. (A)
Transmigratory activity of HepG2 cells (7 x 104) in the presence (U) or
absence (El) of HUVECs. (B) Transmigratory activity of HepG2 cells in the
presence (U) or absence (Ol) of 20 ng mi-' rHGF. The cells appearing on the
lower surface of the filters were stained with Giemsa, and the number of cells
was counted in five visual fields under a microscope (x 200). Each resuh
represents the median value above the number of cells exuded when
collagen was omitted
are described as acting primarily on the leucocytes, and little liter-
ature reporting their action on epithelial cells is available.
Hepatocyte growth factor (HGF) was first identified as a potent
stimulator of hepatocyte growth and DNA synthesis (Matsumoto
and Nakamura, 1992). Following its purification and sequencing,
its identity with scatter factor was established (Nakamura et al,
1989). It is well established that HGF is produced by endothelial
cells as well as fibroblasts and macrophages (Noji et al, 1990;
Matsumoto et al, 1992). HGF produced by the endothelial cells
was even suggested to affect the adhesive activity of lymphocytes
at the vessel wall (Adams et al, 1994). Various inflammatory
cytokines, including IL-1,B3, are known to stimulate the production
of HGF (Matsumoto et al, 1992). In this context, it is notable that
the expression of E-selectin, which plays an important role as
a ligand for carbohydrate antigens in the adhesion to cancer cells,
is also induced by inflammatory cytokines, such as IL-i1,
(Bevilacqua et al, 1989). Taken together, it is surmised that
production of HGF is enhanced at the vascular endothelium that
expresses E-selectin. The possibility that cancer cells, such as
HepG2, eventually produce HGF in response to some stimuli
exerted by activated endothelial cells remains.
In line with the increase in the a251 integrin expression, the
attachment of HepG2 cells to collagen was enhanced by the addi-
tion ofrHUF. We also carried out a chemoinvasion assay using an
experimental system that resembles the in vivo condition ofcancer
cell transmigration at the vessel wall. When collagen was used as
the chemoattractant, the invasion of HepG2 cells was greatly
enhanced by co-cultivation with HUVEC monolayers. A similar
level of enhancement in transmigratory activity was observed by
the addition of rHGF to HepG2 cells. These findings suggest that
HGF facilitates exudation of HepG2 cells into extravascular
tissues. HGF is known to enhance cell mobility (Tajima et al, 1992;
Shibamoto et al, 1992), and a part ofthis activity would be related
to its effect on integrin expression as described in this study.
Recent evidence suggests that HGF increases the motility and
invasiveness ofcancer cells both under in vitro and in vivo condi-
tions (Tajima et al, 1992; Shibamoto et al, 1992; Yoshinaga et al,
1993; Yamashita et al, 1994). In this study, we propose that HGF
would also be involved in thehaematogenous metastasis ofcancer,
atthe step ofadhesion ofcancer cells to endothelial cells. HGF has
been demonstrated as displaying a variety of biological activities
on various target cell types, including epithelial neoplasma
(Tajima et al, 1992; Shibamoto et al, 1992; Yoshinaga et al, 1993).
The wide spectrum of targets of HGF corresponds to the expres-
sion of its receptor, a tyrosine kinase, first described as the c-met
proto-oncogene product. Several investigators reported that ampli-
fication of the c-met proto-oncogene may participate in carcino-
genesis and progression of gastric cancer (Kuniyasu et al, 1992),
colorectal cancer (Liu et al, 1992) and thyroid cancer (Di Renzo et
al, 1992). This would also imply that the HGF-mediated enhance-
ment of integrin expression would be limited to the cancer cells
that express the c-met oncogene product. In our hands, HGF
exerted a similar effect on some cancer cells, such as A431 cells,
besides HepG2, but had no effect on some other cancer cells. For
such cancercells thatdo notrespond to HGF, othercytokines, such
as KGF, heparin-binding EGF (HB-EGF) or amphiregulin, can be
considered as candidates for the cytokines that act in the second
step ofadhesion. These cytokines share characteristics common to
HGF in that their main target is epithelial cells and they are
produced by endothelial cells and associated with proteoglycan-
like structures at the endothelial cell surface. Our preliminary
results indicated that HB-EGF had an enhancing effect on integrin
expression on some oesophageal and breast cancer cells (T Narita,
N Kawakami and R Kannagi, manuscript in preparation). The cell
lineage restriction in the action ofHGF and other cytokines in the
second step of cell adhesion is in contrast to the situation in the
first step of adhesion, in which the selectin-mediated adhesion of
cancer cells to endothelial cells is commonly observed in a wide
range ofepithelial cancer cells.
ABBREVIATIONS
Abbreviations E-selectin (ELAM-1), endothelial-leucocyte adhe-
sion molecule 1; ICAM-1, intercellular adhesion molecule 1;
VCAM-1, vascular cell adhesion molecule 1; LFA-1, lymphocyte
function-associated antigen 1; VLA-4, very-late antigen 4; HUVEC,
human umbilical vein endothelial cell; IL-1, interleukin 1.
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